Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center

Clinical Parkinsonism & Related Disorders · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles